Director/PDMR Shareholding

20 March 2020 07:00 GMT

 

Transaction by Person Discharging Managerial Responsibilities

Disclosure under Article 19 of the EU Market Abuse Regulation

 

AstraZeneca PLC (the Company) announced that, on 19 March 2020, it was notified by Tony Mok, a Non-Executive Director of the Company, that, on 18 March 2020, Mr Mok purchased 1,000 of the Company's American Depositary Shares (ADSs) at a price of $38.32 per ADS. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company.

 

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

 

1  Details of the person discharging managerial responsibilities / person closely associated 
a)  Name   Tony Mok
2  Reason for the notification 
a)  Position/status   Non-Executive Director
b)  Initial notification /Amendment   Initial notification
3  Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)  Name   AstraZeneca PLC
b)  LEI   PY6ZZQWO2IZFZC3IOL08
4  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
a)  Description of the financial instrument, type of instrument Identification code   AstraZeneca PLC American Depositary Shares  CUSIP: 046353108
b)  Nature of the transaction   Purchase of AstraZeneca PLC American Depositary Shares
c)  Price(s) and volume(s)    
Price(s)  Volume(s)
US$38.32 1,000
  
d)  Aggregated information  - Aggregated volume  - Price   Not applicable - single transaction 
e)  Date of the transaction   18 March 2020
f)  Place of the transaction   NYSE

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Media Relations    
Gonzalo Viña   +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Angela Fiorin BioPharmaceuticals +44 1223 344 690
Jennifer Hursit Other +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations    
Thomas Kudsk Larsen   +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharmaceuticals(Cardiovascular, Metabolism) +44 203 749 5711
Nick Stone BioPharmaceuticals (Renal) Environmental, Social and Governance +44 203 749 5716
Josie Afolabi BioPharmaceuticals (Respiratory)  +44 203 749 5631
Tom Waldron Other medicines +44 7385 033 717
Craig Marks FinanceFixed income +44 7881 615 764
Jennifer Kretzmann Corporate accessRetail investors +44 203 749 5824
US toll-free   +1 866 381 72 77


Adrian Kemp
Company Secretary
AstraZeneca PLC

 


 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com

Subscribe

Documents & Links